Hand, Foot and Mouth Disease - Pipeline Review, H1 2020
Hand, Foot and Mouth Disease - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H1 2020, provides an overview of the Hand, Foot and Mouth Disease (Infectious Disease) pipeline landscape.
Hand, foot and mouth disease is an illness that causes sores in or on the mouth and on the hands, feet, and legs. Hand, foot and mouth disease (HFMD) is most commonly caused by coxsackievirus A16, a member of the enterovirus family. Symptoms include fever, headache, loss of appetite and ulcers in the throat (including tonsils), mouth, and tongue. Treatment includes antibiotics and pain relievers.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hand, Foot and Mouth Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.
Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H1 2020, provides an overview of the Hand, Foot and Mouth Disease (Infectious Disease) pipeline landscape.
Hand, foot and mouth disease is an illness that causes sores in or on the mouth and on the hands, feet, and legs. Hand, foot and mouth disease (HFMD) is most commonly caused by coxsackievirus A16, a member of the enterovirus family. Symptoms include fever, headache, loss of appetite and ulcers in the throat (including tonsils), mouth, and tongue. Treatment includes antibiotics and pain relievers.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hand, Foot and Mouth Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.
Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hand, Foot and Mouth Disease (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hand, Foot and Mouth Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hand, Foot and Mouth Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hand, Foot and Mouth Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hand, Foot and Mouth Disease - Overview
Hand, Foot and Mouth Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hand, Foot and Mouth Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hand, Foot and Mouth Disease - Companies Involved in Therapeutics Development
Adimmune Corp
Beijing Minhai Biotechnology Co Ltd
Changchun Bcht Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
CJ HealthCare Corp
Emergex Vaccines Ltd
Sentinext Therapeutics Sdn Bhd
Shanghai Zerun Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Hand, Foot and Mouth Disease - Drug Profiles
(coxsackievirus [serotype A16] + enterovirus [serotype 71]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-1108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-40010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DC-07090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-71 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enterovirus [serotype 71] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enterovirus [serotype EV-71/C4] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enterovirus [serotype EV-A71] (virus like particle, bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enterovirus [serotype EV-A71] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hand, foot and mouth disease (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hand, foot and mouth disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Hand, Foot and Mouth Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MAP2K1 for Hand, Foot and Mouth Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hand, Foot and Mouth Disease - Dormant Projects
Hand, Foot and Mouth Disease - Product Development Milestones
Featured News & Press Releases
Mar 11, 2012: Inviragen Reports Top-Line Results From Phase I Trial Of INV21 Vaccine For Treatment Of Hand, Foot And Mouth Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hand, Foot and Mouth Disease - Overview
Hand, Foot and Mouth Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hand, Foot and Mouth Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hand, Foot and Mouth Disease - Companies Involved in Therapeutics Development
Adimmune Corp
Beijing Minhai Biotechnology Co Ltd
Changchun Bcht Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
CJ HealthCare Corp
Emergex Vaccines Ltd
Sentinext Therapeutics Sdn Bhd
Shanghai Zerun Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Hand, Foot and Mouth Disease - Drug Profiles
(coxsackievirus [serotype A16] + enterovirus [serotype 71]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-1108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-40010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DC-07090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-71 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enterovirus [serotype 71] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enterovirus [serotype EV-71/C4] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enterovirus [serotype EV-A71] (virus like particle, bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enterovirus [serotype EV-A71] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hand, foot and mouth disease (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hand, foot and mouth disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Hand, Foot and Mouth Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MAP2K1 for Hand, Foot and Mouth Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hand, Foot and Mouth Disease - Dormant Projects
Hand, Foot and Mouth Disease - Product Development Milestones
Featured News & Press Releases
Mar 11, 2012: Inviragen Reports Top-Line Results From Phase I Trial Of INV21 Vaccine For Treatment Of Hand, Foot And Mouth Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Hand, Foot and Mouth Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Adimmune Corp, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by CJ HealthCare Corp, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Emergex Vaccines Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Shanghai Zerun Biotechnology Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Dormant Projects, H1 2020
Number of Products under Development for Hand, Foot and Mouth Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Adimmune Corp, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by CJ HealthCare Corp, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Emergex Vaccines Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Shanghai Zerun Biotechnology Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Hand, Foot and Mouth Disease - Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development for Hand, Foot and Mouth Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Adimmune Corp
Beijing Minhai Biotechnology Co Ltd
Changchun Bcht Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
CJ HealthCare Corp
Emergex Vaccines Ltd
Sentinext Therapeutics Sdn Bhd
Shanghai Zerun Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Number of Products under Development for Hand, Foot and Mouth Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Adimmune Corp
Beijing Minhai Biotechnology Co Ltd
Changchun Bcht Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
CJ HealthCare Corp
Emergex Vaccines Ltd
Sentinext Therapeutics Sdn Bhd
Shanghai Zerun Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
